IASO Bio Secures PMDA Approval for CAR-T Therapy Trial Against Multiple Myeloma

Introduction
In a landmark achievement, IASO Biotechnology, also known as IASO Bio, recently announced that it has received crucial approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA). This clearance is for the initiation of a clinical trial for its pioneering CAR-T cell therapy, Equecabtagene Autoleucel (Eque-cel), specifically targeting second- or third-line treatments for patients suffering from multiple myeloma. This significant milestone reflects IASO Bio's commitment to advancing cancer therapies and enhancing patient outcomes worldwide.

Overview of the Clinical Trial
The approved clinical trial, designated as CT103AC004, is structured as a multi-center, randomized, open-label Phase III study. Its primary aim is to assess the efficacy and safety of Eque-cel compared to existing standard treatments in patients diagnosed with relapsed or refractory multiple myeloma. This cohort of patients will have already received one or two lines of prior treatments and have shown refractoriness to lenalidomide, a commonly used medication in multiple myeloma therapy.

Originally initiated in China back in June 2024, the trial has shown promising progress. The strategic study design emphasizes an international collaboration that seeks to foster global insights into the potential of Eque-cel as a robust treatment option.

Regulatory Strategy in Japan
In terms of its regulatory approach within Japan, IASO Bio aims to utilize an efficient review and registration framework. By integrating small-sample clinical trials with supportive global data, the company seeks to significantly minimize the necessary investment typically associated with independent research and development within the country. This strategy is expected to facilitate an expedited process for marketing approval, allowing patients to access novel therapy sooner.

Comments from Leadership
Ms. Jinhua Zhang, Founder, Chairperson, and CEO of IASO Bio, expressed her optimism regarding the approval: “Following the CTN clearance for Eque-cel in late-line relapsed/refractory multiple myeloma in Japan achieved in October 2025, this subsequent clearance for second- or third-line indications further demonstrates PMDA’s recognition of the clinical value of our product and the strength of data originating from China.” Ms. Zhang went on to highlight the potential impact of this therapy, noting that it establishes a solid foundation for the efficient global advancement of their products via a Multi-Regional Clinical Trial (MRCT) pathway.

Understanding Multiple Myeloma
Multiple myeloma (MM) ranks as the second most prevalent hematologic malignancy worldwide. Recent data from Globocan indicates that the global incidence rate of MM was recorded at 1.8 per 100,000 individuals in 2022, while Japan reported a slightly lower incidence rate of 1.5 per 100,000. Although advancements have been made in anti-myeloma treatment options, the disease continues to pose a major therapeutic challenge, primarily due to its relapsing nature and the tendency for patients to develop resistance to various drug classes. This persistent challenge underscores the increasing need for new and effective treatment alternatives.

About Equecabtagene Autoleucel (Eque-cel)
Eque-cel is an innovative CAR-T cell therapy that efficiently targets the surface protein BCMA (B-cell maturation antigen) utilizing a fully human configuration. This approach involves transfecting patients’ autologous T-cells via a lentivirus vector. The genetic construct of Eque-cel includes a fully human scFv, CD8α hinge, 4-1BB co-stimulatory domains, and CD3ζ activation components. Rigorous pre-clinical evaluations point to Eque-cel's capability to enable enhanced and deeper therapeutic responses while maintaining manageable safety profiles, signifying a new frontier in multiple myeloma treatment.

About IASO Bio
Founded in 2017, IASO Bio stands out as a pioneering biopharmaceutical enterprise within the Advanced Therapy Medicinal Product (ATMP) sector, dedicated to transforming breakthrough innovations from China into accessible healthcare solutions on a global scale. The company specializes in novel cell therapies and biologics aimed at treating hematological malignancies and autoimmune disorders. Its extensive product pipeline, including Eque-cel and other promising candidates, emphasizes its commitment to providing impactful therapies to patients in need. Additionally, IASO Bio is actively collaborating with renowned biotechnology partners and premier academic institutions to enhance its development capabilities, marking its trajectory toward becoming a leader in the therapeutic landscape.

Conclusion
The clearance for the CAR-T therapy clinical trial by IASO Bio represents a large step forward in the fight against multiple myeloma, amplifying hopes for patients in Japan and beyond. As IASO Bio moves forward with its innovative treatments, the anticipated results of this clinical trial may provide transformative outcomes for patients battling this challenging illness.